Resolution of Gouty Inflammation

痛风炎症的解决

基本信息

  • 批准号:
    7305163
  • 负责人:
  • 金额:
    $ 24.83万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2007
  • 资助国家:
    美国
  • 起止时间:
    2007-07-01 至 2009-06-30
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): With new concepts and evolving methodologies, this laboratory has kept returning over 4 decades to the study of acute gouty arthritis, both for its intrinsic importance and as a model of the acute inflammatory response. In this application, we evaluate the pathogenesis of acute gouty (and pseudogouty) arthritis in the light of recent advances in pathways of lipid metabolism, to explain clinical facts of gout - specifically, why untreated attacks typically subside despite the continued presence of urate crystals. The interaction of urate crystals with leukocytes leads to the generation of endogenous pro-inflammatory lipid (leukotrienes, prostaglandins) and other mediators that propagate and amplify the inflammatory response. We hypothesize that early lipid mediators sow the seeds for later ones (lipoxins and perhaps novel moieties) with anti-inflammatory properties, leading to resolution. We suggest further that this reprogramming of lipid mediators may explain in part the action of therapeutic agents such as colchicine. In Aim 1 we will employ lipidomic analysis via LC-UV-tandem mass spectrometry to examine the lipid mediators generated in vitro by the interaction of monosodium urate or calcium pyrophosphate crystals (gout and pseudogout, respectively) with human neutrophils (PMN) over time. In Aim 2 we will examine spectrometrically the effects of colchicine and other anti-inflammatory agents (aspirin, glucocorticoids) on the generation of pro- and anti-inflammatory lipid mediators. The larger significance of this work is as prologue to the use of novel anti-inflammatory agents based on the endogenous lipid mediators studied here. Such agents, based on natural mediators, are likely to be less toxic than the therapeutic modalities currently available. The control of gouty inflammation then becomes a model for a new approach to anti-inflammatory therapy. We are employing recent advances in pathways of lipid metabolism, to explain clinical facts of the common disease, acute gouty arthritis. We hypothesize that early inflammatory lipid mediators sow the seeds for later ones with anti-inflammatory properties, leading to resolution. We suggest further that this reprogramming of lipid mediators may explain in part the action of therapeutic agents such as colchicine, and could lead to better treatment for this condition.
描述(由申请人提供):随着新概念和不断发展的方法,该实验室在40多年来一直致力于急性痛风性关节炎的研究,这既是因为其内在的重要性,也是因为其作为急性炎症反应模型。在本申请中,我们根据脂质代谢途径的最新进展评估急性痛风(和假性痛风)关节炎的发病机制,以解释痛风的临床事实-特别是,为什么未经治疗的攻击通常会消退,尽管持续存在尿酸盐晶体。尿酸盐晶体与白细胞的相互作用导致内源性促炎脂质(白三烯、白藜芦醇)和其他介质的产生,这些介质传播并放大炎症反应。我们假设早期的脂质介体为后来具有抗炎特性的脂质介体(脂氧素和可能的新型部分)播下了种子,从而导致解决。我们进一步建议,这种脂质介质的重新编程可以部分解释治疗剂,如秋水仙碱的作用。在目的1中,我们将采用脂质组学分析,通过LC-UV-串联质谱法来检查体外产生的脂质介质的相互作用,尿酸盐或焦磷酸钙晶体(痛风和假痛风,分别)与人中性粒细胞(PMN)随着时间的推移。在目标2中,我们将通过光谱法研究秋水仙碱和其他抗炎剂(阿司匹林,糖皮质激素)对促炎和抗炎脂质介质产生的影响。这项工作的更大意义是作为序幕,使用新的抗炎剂的基础上内源性脂质介质在这里研究。这种基于天然介质的药物可能比目前可用的治疗方式毒性更小。痛风炎症的控制,然后成为一种新的抗炎治疗方法的模型。我们采用脂质代谢途径的最新进展,解释常见疾病急性痛风性关节炎的临床事实。我们假设早期炎症脂质介质为后来的抗炎特性播下种子,导致解决。我们进一步建议,这种脂质介质的重新编程可以部分解释治疗药物如秋水仙碱的作用,并可能导致更好的治疗这种情况。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

STEPHEN E. MALAWISTA其他文献

Microtubule Crystals: A New Biophysical Phenomenon induced by Vinca Alkaloids
微管晶体:长春花生物碱诱导的一种新的生物物理现象
  • DOI:
    10.1038/2181176a0
  • 发表时间:
    1968-06-22
  • 期刊:
  • 影响因子:
    48.500
  • 作者:
    KLAUS G. BENSCH;STEPHEN E. MALAWISTA
  • 通讯作者:
    STEPHEN E. MALAWISTA

STEPHEN E. MALAWISTA的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('STEPHEN E. MALAWISTA', 18)}}的其他基金

Acute Inflammation by Human Leukocytes in Human Skin Xenografts
人类皮肤异种移植物中人类白细胞的急性炎症
  • 批准号:
    7608580
  • 财政年份:
    2008
  • 资助金额:
    $ 24.83万
  • 项目类别:
Resolution of Gouty Inflammation
痛风炎症的解决
  • 批准号:
    7460795
  • 财政年份:
    2007
  • 资助金额:
    $ 24.83万
  • 项目类别:
HOST-PARASITE INTERACTIONS THAT DETERMINE THE RATE OF B BURGDORFERI IN VIVO
决定体内伯氏疏螺旋体比率的宿主-寄生虫相互作用
  • 批准号:
    6099483
  • 财政年份:
    1999
  • 资助金额:
    $ 24.83万
  • 项目类别:
LYME DISEASE--HOST PARASITE INTERACTIONS
莱姆病——宿主寄生虫相互作用
  • 批准号:
    2852900
  • 财政年份:
    1999
  • 资助金额:
    $ 24.83万
  • 项目类别:
LYME DISEASE--HOST PARASITE INTERACTIONS
莱姆病——宿主寄生虫相互作用
  • 批准号:
    6163958
  • 财政年份:
    1999
  • 资助金额:
    $ 24.83万
  • 项目类别:
LYME DISEASE--HOST PARASITE INTERACTIONS
莱姆病——宿主寄生虫相互作用
  • 批准号:
    6632125
  • 财政年份:
    1999
  • 资助金额:
    $ 24.83万
  • 项目类别:
HOST-PARASITE INTERACTIONS THAT DETERMINE THE RATE OF B BURGDORFERI IN VIVO
决定体内伯氏疏螺旋体比率的宿主-寄生虫相互作用
  • 批准号:
    6268037
  • 财政年份:
    1998
  • 资助金额:
    $ 24.83万
  • 项目类别:
HOST-PARASITE INTERACTIONS THAT DETERMINE THE RATE OF B BURGDORFERI IN VIVO
决定体内伯氏疏螺旋体比率的宿主-寄生虫相互作用
  • 批准号:
    6234977
  • 财政年份:
    1997
  • 资助金额:
    $ 24.83万
  • 项目类别:
MOTILE FUNCTION OF NEUTROPHILS AND CYTOPLASTS
中性粒细胞和细胞质的运动功能
  • 批准号:
    2292523
  • 财政年份:
    1995
  • 资助金额:
    $ 24.83万
  • 项目类别:
PATHOGENESIS OF LYME DISEASE--MOLECULAR PROBES
莱姆病的发病机制--分子探针
  • 批准号:
    3160837
  • 财政年份:
    1990
  • 资助金额:
    $ 24.83万
  • 项目类别:

相似海外基金

Improving Acute Disease Management for Patients with Alzheimer's Disease and Related Dementias
改善阿尔茨海默病和相关痴呆症患者的急性疾病管理
  • 批准号:
    10712647
  • 财政年份:
    2001
  • 资助金额:
    $ 24.83万
  • 项目类别:
INDUCTION OF ACUTE DISEASE IN MACAQUES BY NEF GENE VARIANT OF SIVMAC239
SIVMAC239 的 NEF 基因变体在猕猴中诱导急性疾病
  • 批准号:
    6247642
  • 财政年份:
    1997
  • 资助金额:
    $ 24.83万
  • 项目类别:
INDUCTION OF ACUTE DISEASE IN MACAQUES BY NEF GENE VARIANT OF SIVMAC239
SIVMAC239 的 NEF 基因变体在猕猴中诱导急性疾病
  • 批准号:
    3718999
  • 财政年份:
  • 资助金额:
    $ 24.83万
  • 项目类别:
Neurophysiological alterations in multiple sclerosis patients during acute disease acivity
多发性硬化症患者急性疾病活动期间的神经生理学变化
  • 批准号:
    465668867
  • 财政年份:
  • 资助金额:
    $ 24.83万
  • 项目类别:
    Research Grants
SIVMAC 1NEF ALLELE: LYMPHOCYTE ACTIVATION & ACUTE DISEASE IN MACAQUE MONKEYS
SIVMAC 1NEF 等位基因:淋巴细胞激活
  • 批准号:
    3719026
  • 财政年份:
  • 资助金额:
    $ 24.83万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了